For research use only. Not for therapeutic Use.
PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM[1].
PDE9-IN-1 is excellent selectivity across PDE families[1].
PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function[1].
| Catalog Number | I019153 |
| CAS Number | 2305087-92-5 |
| Synonyms | 1-cyclopentyl-6-[[(2R)-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-5H-pyrazolo[3,4-d]pyrimidin-4-one |
| Molecular Formula | C17H23FN6O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H23FN6O2/c1-10(16(26)23-7-6-11(18)9-23)20-17-21-14-13(15(25)22-17)8-19-24(14)12-4-2-3-5-12/h8,10-12H,2-7,9H2,1H3,(H2,20,21,22,25)/t10-,11+/m1/s1 |
| InChIKey | HOQGZKUBNCAZBE-MNOVXSKESA-N |
| SMILES | CC(C(=O)N1CCC(C1)F)NC2=NC3=C(C=NN3C4CCCC4)C(=O)N2 |
| Reference | [1]. Wu Y, et al. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. J Med Chem. 2019 Apr 25;62(8):4218-4224. |
